|Title||TAKE A CLOSER LOOK|
|Product / Service||KETESSE|
|Category||E01. Pharma, Vaccines & Biotech aimed at Healthcare Professionals|
|Entrant||H&T MELBOURNE (THE HEALTHY THINKING GROUP) Melbourne, AUSTRALIA|
|Idea Creation||H&T MELBOURNE (THE HEALTHY THINKING GROUP) Melbourne, AUSTRALIA|
|Jason Kilgour||H&T Melbourne||Creative Director|
Because the key benefit of Ketesse is how it was developed at a molecular level. We created an idea where the USP of Ketesse could only be viewed when you take a closer look at the drug. By using VR, A microscope quiz, building the molecule and a talk from the head of Menarini from Italy all helped to prove why this drug should be marketed at a high level within the Menarini group.
See case study.
The key stakeholders agreed that Ketesse is a drug that has been overlooked. In Malaysia the drug has seen sales growth to number one and the other regions will look at an increased investment to simulate this success.
Ketesse had great potential as an NSIAD, but a lack of internal engagement meant it was not translating to sales growth. Our task was to reignite the passion for Ketesse amongst the Menarini group. So we asked the key stakeholders across Asia Pacific to come together to ‘Take a closer look’ at Ketesse. We held an event which allowed them to physically take a closer look at the benefits an USP of Ketesse which in turn will drive them to invest money to market the drug.
By gathering the Key stakeholders across Asia Pacific we could promote the benefits of Ketesse and reignite the passion for Ketesse.